NASDAQ:ORKA Oruka Therapeutics Q3 2026 Earnings Date & Estimates $80.15 -1.00 (-1.23%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$80.28 +0.13 (+0.16%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Oruka Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Oruka Therapeutics in Q3 2026Oruka Therapeutics is expected to post earnings of -$0.5994 per share. In the same quarter a year earlier Oruka Therapeutics reported -$0.55 per share. Oruka Therapeutics last reported on August 10, 2026, posting -$0.55 per share and missing the -$0.5125 consensus estimate. Oruka Therapeutics has beaten the consensus EPS estimate in 6 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.5994Prior-Year EPS-$0.55Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.55 (Missed by -$0.0375)EPS Beat Rate6 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Oruka Therapeutics Q3 2026 Earnings FAQ When does Oruka Therapeutics report Q3 2026 earnings? Oruka Therapeutics (NASDAQ:ORKA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Oruka Therapeutics' Q3 2026 earnings call? Oruka Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Oruka Therapeutics? Analysts expect Oruka Therapeutics to post earnings of -$0.5994 per share for Q3 2026. Oruka Therapeutics Earnings HeadlinesOruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book ValueOctober 20, 2026 | finance.yahoo.comBTIG Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)October 19, 2026 | theglobeandmail.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 25 at 1:00 AM | Digest Publishing (Ad)BTIG Research Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)October 19, 2026 | americanbankingnews.comOruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far EndOctober 18, 2026 | seekingalpha.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $523,670.00 in StockOctober 18, 2026 | americanbankingnews.comSee More Oruka Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email. Email Address About Oruka TherapeuticsOruka Therapeutics (NASDAQ:ORKA) (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies. Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases. Its lead programs include ORKA-001, an extended-duration IL-17A inhibitor, and ORKA-002, an extended-duration IL-17A/F inhibitor. These candidates are being developed for potential use in multiple inflammatory and immune-related disorders. Oruka is advancing its programs through clinical development and does not yet have an approved commercial product. The company’s activities are primarily focused on research, clinical trials and the development of its antibody platform for patients in the United States and potentially other international markets.View Oruka Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
